This is therefore a comparing of the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership in Sutro Biopharma Inc. (NASDAQ:STRO) and CRISPR Therapeutics AG (NASDAQ:CRSP). The two are both Biotechnology companies that compete with one another.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sutro Biopharma Inc.||11||0.19||9.29M||-1.66||0.00|
|CRISPR Therapeutics AG||55||0.00||34.37M||-3.74||0.00|
Demonstrates Sutro Biopharma Inc. and CRISPR Therapeutics AG earnings per share, gross revenue and valuation.
Table 2 provides the net margins, return on equity and return on assets of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Sutro Biopharma Inc.||88,056,872.04%||0%||0%|
|CRISPR Therapeutics AG||62,388,818.30%||-50.9%||-39.8%|
5.7 and 5.7 are the respective Current Ratio and a Quick Ratio of Sutro Biopharma Inc. Its rival CRISPR Therapeutics AG’s Current and Quick Ratios are 15.8 and 15.8 respectively. CRISPR Therapeutics AG has a better chance of clearing its pay short and long-term debts than Sutro Biopharma Inc.
The next table highlights the given recommendations and ratings for Sutro Biopharma Inc. and CRISPR Therapeutics AG.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Sutro Biopharma Inc.||0||0||1||3.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
Sutro Biopharma Inc.’s upside potential is 58.26% at a $16 average target price. On the other hand, CRISPR Therapeutics AG’s potential downside is -8.11% and its average target price is $66.5. The information presented earlier suggests that Sutro Biopharma Inc. looks more robust than CRISPR Therapeutics AG as far as analyst view.
Institutional & Insider Ownership
Sutro Biopharma Inc. and CRISPR Therapeutics AG has shares held by institutional investors as follows: 73.1% and 50%. About 21.23% of Sutro Biopharma Inc.’s share are held by insiders. Comparatively, insiders own roughly 2% of CRISPR Therapeutics AG’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Sutro Biopharma Inc.||1.9%||-4.09%||13.27%||5.52%||0%||24.94%|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Sutro Biopharma Inc. has weaker performance than CRISPR Therapeutics AG
Sutro Biopharma Inc. beats CRISPR Therapeutics AG on 7 of the 11 factors.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.